Mymetics Corp (MYMX)

[Work Harder]

Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304289/

FranÇois Spertin

Iemoli et al. [19] investigated the safety and clinical efficacy of sublingual grass allergy tablet immunotherapy in a group of HIV-positive patients with allergic rhinitis receiving antiretroviral therapy. HIV infection was considered a relative contraindication for AIT; however, highly active antiretroviral treatment has meanwhile improved immune function and life expectancy of HIV-infected patients so much that an attempt at therapy seems reasonable, especially since the incidence of allergic airway diseases in HIV-infected patients is comparable to that of the general population [19]. Data on clinical efficacy showed a significant improvement of patients treated with SLIT compared to controls, but no significant change in the number of CD4-positive T cells and HIV viral load in both groups was observed. These data show that SLIT can be effective, safe, and well-tolerated in viro-immunologically controlled HIV-positive patients.

In contrast, virus-like particles (VLPs) as modern vaccine components can even be used in the AIT of airborne and food allergens (peanut) in the near future [21, 22].

Conflict of interest

R. Buhl: Lectures for and/or consultancy of AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Novartis, Roche, Sanofi, and Teva; Research support for Universitätsmedizin Mainz: Boehringer Ingelheim, GlaxoSmithKline, Novartis und Roche – unrelated to this paper.

R. Brehler: Lectures for ALK, Allergopharma, Almirall, AstraZeneca, Bencard, Gesellschaft zur Förderung der Dermatologischen Forschung und Fortbildung, Gesellschaft für Information und Organisation, GSK, Dr. Pfleger, HAL, Leti, Merck, Novartis, Oto-Rhino-Laryngologischer Verein, Pierre Fabre, Pohl Boskamp, Stallergenes, Thermo-Fischer; Consultancy for Allergopharma, Bencard, HAL, Leti, Novartis; Clinical studies for Allergopharma, Bencard, Biotech Tools, Genentech, Leti, Novartis, Circassia – unrelated to this paper.

U. Darsow was lecturer, principal investigator, and consultant for ALK Abello, Bencard, and Novartis Pharma – unrelated to this paper.

T. Jakob received grants, personal fees, or non-financial support from Novartis, ALK-Abelló, Bencard/Allergy Therapeutics, Allergopharma, Thermo Fisher Scientific, and Celgene – unrelated to this paper.

M. Jutel: Personal fees from ALKAbello, Allergopharma, Stallergenes, Anergis, Allergy Therapeutics, Circassia, Leti, Biomay, and HAL – during the conduct of this study; Personal fees from AstraZeneka, GSK, Novartis, Teva, Vectura, UCB, Takeda, Roche, Janssen, Medimmune, and Chiesi – unrelated to this paper.

L. Klimek: Grants and/or personal fees from Allergopharma, MEDA/ Mylan, HAL Allergie, ALK Abelló, Leti, Stallergenes, Quintiles, Sanofi, ASIT biotech, Lofarma, Allergy Therapeut., Astra- Zeneca, GSK, Inmunotk – unrelated to this paper; Member of the following organizations: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO-BV GPA, EAACI.

S. Lau: Consultant for Allergopharma.

P. Matricardi: Grants and/or personal fees from DFG, Hycor, Omron, Stallergens, Euroimmun, Novartis, TPS, Stallergenes- Greer – unrelated to this paper; Non-financial support from Thermo Fisher Scientific – unrelated to this paper.

O. Pfaar reports to have received research grands and/or personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/ Allergy Therapeutics, Lofarma, Biomay, Circassia, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, MEDA Pharma/ MYLAN, Anergis S.A., Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, Glaxo Smith Kline, Astellas Pharma Global, EUFOREA, Roxall, Novartis, Sanofi Aventis, Med Update Europe GmbH und streamedup! GmbH for the past 36 months – unrelated to this paper.

Merck Successfully Divests Allergopharma

https://www.allergopharma.com/news/details/news/merck-successfully-divests-allergopharma/

The allergy business of Merck in Europe was transferred to Dermapharm on March 31. The transfer of the Allergopharma business in China is planned for the second half of 2020. The two parties have agreed not to disclose the purchase price.